- Home
- NCEL vs RLYB Comparison
NCEL vs RLYB Comparison
Compare NCEL & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NCEL | RLYB |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.7M | 24.1M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NCEL | RLYB |
|---|---|---|
| Price | $2.59 | $0.77 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 90.9K | ★ 193.8K |
| Earning Date | 12-01-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $674,000.00 |
| Revenue This Year | N/A | $17.61 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 12.71 |
| 52 Week Low | $2.48 | $0.22 |
| 52 Week High | $7.64 | $1.08 |
Technical Indicators
Market Signals| Indicator | NCEL | RLYB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 60.47 |
| Support Level | N/A | $0.71 |
| Resistance Level | N/A | $0.80 |
| Average True Range (ATR) | 0.00 | 0.05 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 77.94 |
Price Performance
Historical ComparisonAbout NCEL NewcelX Ltd. Ordinary Shares
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.